Abstract: A series of p-cymene ruthenium(II) complexes with imidazol-2-yl phosphines as PN ligands was prepared. Depending on the number of imidazolyl substituents in the ligands Ph3-nP(im)(n) 1-3: n = 1-3, im imidazol-2-yl (a), 1-methylimidazol-2-yl (b) different coordination modes were observed: kappa P, kappa N-2,N or kappa N-3,N,N. The complexes were tested for their cytotoxicity in different cancer cell lines. Most of the compounds were found to be non-toxic; The compounds (p-cymene)Ru(1a)Cl-2] (4a) shows cytotoxicity towards A2780sens and Hct116 cells in the mM range but not in H4IIE cells. 
Introduction
Since the authorization of cisplatin in 1978, the interest in and development of metal-based drugs prospers consistently. Still, cisplatin, cis-[Pt(NH 3 ) 2 Cl 2 ], and its analogs, especially oxaliplatin and carboplatin, are basic chemotherapeutics in combination therapy. [1] [2] [3] The therapeutic effect of cisplatin is based on DNA platination which triggers apoptosis. [4] The major draw-back for a successful chemotherapy by platinum-based drugs is acquired resistance towards the applied drug during the course of therapy. [5] In order to circumvent those resistance mechanisms drugs, which address alternative cellular targets have to be developed. [6] [7] [8] The most promising metallodrugs besides cisplatin analogues are ruthenium-based drugs. [9, 10, [10] [11] [12] [13] Compounds of Ru(II) and Ru(III) are able to overcome cisplatin resistance.
Their cytotoxicity and antimetastatic properties are combined with low overall toxicity. [9, [14] [15] [16] [17] Trans-[RuCl 4 (dmso)(Im)]ImH (NAMI-A, where Im = imidazole) has completed phase I clinical trials. [18] Interestingly, NAMI-A is more active against metastases than against primary tumours. [19] Half-sandwich Ru(II) arene complexes of the type [(η 6 -arene)Ru(YZ)(X)], where YZ is a bidentate chelating ligand and X is a good leaving group, show promising in vitro and in vivo anticancer activity. [16] These compounds coordinate to guanine N7 of DNA, which can be complemented by intercalative binding of an extended arene, as well as specific hydrogen-bonding interactions. [20, 21] For example, increasing the size of the coordinated arene is accompanied by an increase in activity in human ovarian cancer cell lines [16] and the nature of the chelating ligand YZ and leaving group X seems influence their kinetics and even can change their nucleobase selectivity. [22] The RAPTA family of organometallic Ru(II) compounds contain the water-soluble phosphine ligand phosphaadamantane (pta) or derivatives thereof. Usually these compounds exhibit moderate in vitro activity, and some compounds show no activity in healthy cells up to millimolar concentrations. The pta compounds show little activity against primary tumours in vivo, although they exhibit some capacity to reduce lung metastases derived from a mammary carcinoma xenograft grown in mice. [23] The cytotoxicity of [Ru(η 6 -p-cymene)Cl 2 (pta)], in EAC cells is thought to be mediated by mitochondrial and Jun-N (amino)-terminal kinase (JNK)-p53 pathways. [24] For all Ru(II) compounds it is believed that in vivo, analogous to cisplatin, aquation of the chlorido complex is largely suppressed in intracellular fluids (with chloride concentrations are about 100 mM), whereas in the cell nucleus with a much lower chloride concentration (ca. 4 mM) the active aqua species forms. [25, 26] Although their mechanism of action is still largely unknown, there is some evidence that RAPTA compounds work on molecular targets other than DNA, [27] [28] [29] implying a biochemical mode of action profoundly different from classical platinum anticancer drugs.
We are currently examining the use of imidazole-based PN ligands in biomedical applications [30] [31] [32] as well as in catalysis [33, 34] . Here we present coordination chemistry of these PN ligands towards (η 6 -cymene)Ru(II) and basic cytotoxicity studies in different cancer cell lines.
Experimental Section
The ligands Ph 3-n P(im) n {1-3: n = 1-3, im = imidazol-2-yl (a), 1-methylimidazol-2-yl (b)} and [(cym)Ru(P-1b)Cl 2 ] (4b) were prepared according published procedures. [32, [34] [35] [36] [37] All reactions were carried out in Schlenk tubes under an atmosphere of dry nitrogen using anhydrous solvents purified according to standard procedures. All chemicals were purchased from commercial sources and used as received. H} NMR spectra were referenced to external 85% H 3 PO 4 . The MALDI mass spectra were recorded on a Bruker Ultraflex MALDI-TOF mass spectrometer. The elemental composition of the compounds was determined with a PerkinElmer Analysator 2400 at the Institut fu r Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universita t Du sseldorf.
Synthesis of (cym)Ru-complexes

[(cym)Ru(P-1a)Cl 2 ] (4a)
Ligand 1a (83 mg, 0.33 mmol) and [Ru(cym)Cl 2 ] 2 (100 mg, 0.16 mmol) were dissolved in dry CH 2 Cl 2 (15 mL) and stirred for 24 hours. The dark red solution was concentrated to 5 mL and Et 2 O was added. The precipitate was collected and dissolved in thf, filtered and again precipitated upon addition of n-hexane. The red solid was filtered off and dried in vacuo.
Yield: 52 mg (28 %). (27) 
[(cym)Ru(
Distribution coefficients (logD)
The n-octanol-water distribution coefficients of the compounds were determined using a shake-flask method. PBS buffered bi-distilled water (100 mL, phosphate buffer, c(PO 4 3-) = 10 mM, c(NaCl) = 0.15 M, pH adjusted to 7.4 with HCl) and n-octanol (100 mL) were shaken together using a laboratory shaker (Perkin Elmer), for 72 h to allow saturation of both phases.
1 mg of each compound was mixed in 1 mL of aqueous and organic phase, respectively for 10 min using a laboratory vortexer. The resultant emulsion was centrifuged (3000 g, 5 min) to separate the phases. The concentrations of the compounds in the organic and aqueous phases were then determined using UV absorbance spectroscopy (230 nm). LogD pH was defined as the logarithm of the ratio of the concentrations of the complex in the organic and aqueous phases logD = log([compound (org) ]/[compound (aq) ]), the value reported is the mean of three separate determinations.
DNA Binding Studies
The UV/Vis kinetic studies and thermal denaturation temperature 
Cell culture
Hct116 human colon carcinoma and H4IIE rat hepatoma cells were grown in Dulbecco´s modified Eagle´s medium (DMEM, GIBCO; Germany), A2780 human ovarian carcinoma cells were grown in RPMI cell culture medium; all media contained 10 % fetal calf serum (PAA Laboratories; Austria), penicillin (100 U / mL) and streptomycin (100 µg / mL) at 5 % CO 2 and 37 °C.
Determination of cytotoxicity
The effect of the compounds on cell viability was determined using the MTT assay. [39] Cells were plated on 96-multiwell plates (H4IIE, Hct116 cells: 15.000 / well, A2780 cells: 35.000 / well), allowed to attach for 24 h and then treated with different concentrations of the substances for indicated time points. In all experiments compounds were dissolved in dmso.
The dmso concentration was equal at all compound concentrations analyzed. The highest dmso concentration used was 1%; no toxic effect was detected at this concentration. After treatment medium was changed and cells were incubated for 30 min under cell culture conditions with 1 mg / mL MTT. Then the cells were lysed with 100 % dmso. The concentration of reduced MTT as a marker for cell viability was measured photometrically (560 nm) using a Wallace Victor2 1420 multilabel counter (Perkin-Elmer).
Statistical analysis
All data were analyzed using one-way analysis of variance, followed by Bonferroni or Dunnet post hoc analysis to determine statistical significance. P values < 0.05 were considered statistically significant. The analysis was performed with GraphpadPrism 5.0c.
Crystallography
Crystals of compounds 5a and 5a' . CH 2 Cl 2 suitable for X-ray study were selected by means of a polarisation microscope and investigated with a STOE Imaging Plate Diffraction System, using graphite monochromatized MoK radiation ( = 0.71073 Å). Unit cell parameters were determined by least-squares refinements on the positions of 8000 reflections. Space group type no. 14 was uniquely determined for both compounds. Corrections for Lorentz and polarization effects were applied. The structures were solved by direct methods (SHELXS-86) [40] and subsequent F-syntheses. Approximate positions of all the hydrogen atoms were found in different stages of converging refinements by full-matrix least-squares calculations on F 2 . [40] Anisotropic displacement parameters were refined for all atoms heavier than hydrogen. With idealised bonds lengths and angles assumed for all the CH, CH 2 and CH 3 groups, the riding model was applied for the corresponding H atoms and their isotropic displacement parameters were constrained to 120%, 120% and 150% of the equivalent isotropic displacement parameters of the parent carbon atoms, respectively. In addition, the H atoms of the CH 3 groups were allowed to rotate around the neighboring C-C bonds.
Crystallographic data of 5b2CH 3 CN½H 2 O were collected at 183(2) K on an Oxford Diffraction Xcalibur system with a Ruby detector using Mo Kα radiation (λ = 0.7107 Å) that was graphite-monochromated. Suitable crystals were covered with oil (Infineum V8512, formerly known as Paratone N), mounted on top of a glass fibre and immediately transferred to the diffractometer. The program suite CrysAlisPro was used for data collection, multi-scan absorption correction and data reduction. [41] The structure was solved with direct methods using SIR97 [42] and was refined by full-matrix least-squares methods on F 2 with SHELXL-97. [40] The structure was checked for higher symmetry with help of the program Platon. [43] CCDC entries 867104 (5a), 867105 (5a' 
Results and Discussion
Syntheses and characterisation
We 
Solid-state structures
The solid-state structures of compounds 5a', 5a and 5b were determined by single crystal analysis and crystallographic data is summarized in Table 2 . Compounds 5a' and 5a crystallised in the monoclinic space group P2 1 /c. Compound 5b crystallised as solvate (Fig. 2) . In 5a' and 5b the κ is found (Fig. 3 and Fig. 4) . The ruthenium atom is coordinated by 2a/b in the chelating κ [31, 35, [47] [48] [49] and complexes [(cym)Ru(N-N)Cl] + with diammino ligands [31, 50, 51] .
In the solid-state structures of 5a and 5b the phenyl substituents of the corresponding ligand 2a/b and the p-cymene ligand at the ruthenium atom adopt cis (5b) and trans positions (5a') (Scheme 2). The compounds 5a and 5a', bearing ligand 2a with NH functionalities, show hydrogen bonding in their solid-state structures.
In the solid state of 5a' intermolecular hydrogen bonds are formed between N2H1 … O1 (triflate) and N4H2 … Cl1 thus forming one-dimensional arrays. Also in the solid state of 5a the intermolecular hydrogen bonds N3H2 … Cl2 result in formation of one-dimensional arrays.
Additionally a weak bifurcated intramolecular hydrogen bond between N1H1 and Cl1 and Cl2 is found. 
Biological studies
Biological studies were performed on compounds 4a,b, 5a,b and 5a' as well as 6a and 6b.
The n-octanol-water distribution coefficients of compounds 4a,b, 5a,b and 5a' were determined as logD 7.4 values using phosphate buffered saline (PBS). The logD 7.4 value decreases within the series 4a > 4b > 5a' > 5a > 5b ( Table 3 ). The introduction of additional imidazolyl groups in the κP complexes increases the water-solubility of the compounds as does the introduction of charge in complexes 5a/b. Surprisingly, the complexes having Nmethyl groups in the PN ligands are more water soluble than their NH-congeners.
A decrease in thermal denaturation temperature of 7 °C in the presence of 4a, 4b and 5a', respectively and of 4 °C in the presence 5b was recorded for calf-thymus DNA (ctDNA) at a molar ratio of r = 0.2 where [DNA] is given in M(base pairs) ( Table 3 and Supporting Information). Interestingly, the melting curve in the presence of 5a shows two stages corresponding to decreases in thermal denaturation temperature of 8 and 28 °C respectively.
This might reflect a rearrangement of the coordination mode of the ligand in the complex as discussed before. The cytotoxicity of the compound was determined towards three different cell lines using the MTT assay method. For comparison, the compound [(cym)Ru(en)Cl]Cl (7) was also introduced in the cell line studies (Table 4 and Fig. 5 ). Cell lines used were Hct116 human colon carcinoma, H4IIE rat hepatoma and A2780 human ovarian carcinoma cells (cisplatin sensitive). The cytotoxicity values for these compounds fall in the range commonly observed for various Ru(arene)-type complexes. [31, 52, 53] As expected, the complexes coordinatively saturated 6a and 6b are not cytotoxic at concentrations up to 100 µM after 24, 48 and 72 hours of incubation, respectively (Table 4) .
Compounds 5a' and 5b containing  (Table 4 and Fig. 6 ). Reason for the decreased toxicity of compound 5a to 4a might be the hydrophobicity. The selective toxicity of 5a in H4IIE cells might be an effect of 5a in the cell cycle leading to delayed toxic effects. In addition it is well known, that RAPTtype complexes not only act as DNA binders. The poor correlation found here could also point towards a different mechanism, where proteins are favoured targets for the compounds.
For corresponding complexes this has been shown by the groups of Messori and Davey. [29, 56] 5 . Cytotoxic effects 5a, 5a´, 5b and 7 in H4IIE and A2780 cells. H4IIE rat hepatoma and A2780 human ovarian carcinoma cells were incubated with 5a, 5a´, 5b or 7 (100 µM) for 72 h, then MTT reduction as a marker of cell viability was measured (absorbance at 560 nm). Results are expressed as viable cells in percent of control value ± SD. (n = 3, *:p < 0,05 vs. corresponding DMSO control). 
Conclusion
We prepared a series of ruthenium(II) arene complexes with ambidentate PN ligands. All compounds displaying a chelating  
